特拉维尔治疗

最新新闻

• 评级变动
  Evercore Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $78
  \u5e02\u573a\u8d44\u8baf · 2026/8/10
• 评级变动
  CCORF Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $62
  \u5e02\u573a\u8d44\u8baf · 2026/7/30
• Guggenheim Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $89
  \u5e02\u573a\u8d44\u8baf · 2026/9/24
• 评级变动
  A Quick Look at Today's Ratings for Travere Therapeutic(TVTX.US), With a Forecast Between $70 to $90
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  Wedbush Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $61
  \u5e02\u573a\u8d44\u8baf · 2026/7/13
• Wedbush Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $76
  \u5e02\u573a\u8d44\u8baf · 2026/9/22
• Travere Therapeutics: Eric Dube, Ph.D., to Step Down as Pres and CEO in Dec TVTX
  Dow Jones · 2026/9/22
• 评级变动
  J.P. Morgan Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $90
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  TD Cowen Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $60
  \u5e02\u573a\u8d44\u8baf · 2026/7/22
• 评级变动
  Piper Sandler Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $68
  \u5e02\u573a\u8d44\u8baf · 2026/8/17
• BofA Securities Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $71
  \u5e02\u573a\u8d44\u8baf · 2026/9/24
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Maze Therapeutics, Inc. (MAZE) and Immunome (IMNM)
  TipRanks · 2026/8/12
• 评级变动
  Guggenheim Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $65
  \u5e02\u573a\u8d44\u8baf · 2026/6/25
• 评级变动
  A Quick Look at Today's Ratings for Travere Therapeutic(TVTX.US), With a Forecast Between $68 to $85
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• 评级变动
  A Quick Look at Today's Ratings for Travere Therapeutic(TVTX.US), With a Forecast Between $62 to $85
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• 评级变动
  CCORF Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $70
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• H.C. Wainwright Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $67
  \u5e02\u573a\u8d44\u8baf · 2026/10/3
• 评级变动
  Stifel Maintains Travere Therapeutic(TVTX.US) With Hold Rating, Maintains Target Price $62
  \u5e02\u573a\u8d44\u8baf · 2026/8/10
• 评级变动
  Guggenheim Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $65
  \u5e02\u573a\u8d44\u8baf · 2026/7/22
• 评级变动
  BofA Securities Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $64
  \u5e02\u573a\u8d44\u8baf · 2026/7/22

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。